AbbVie bags RINVOQ FDA approval for nr-axSpA in adults
RINVOQ FDA approval for nr-axSpA : AbbVie has bagged approval for its selective JAK inhibitor RINVOQ (upadacitinib 15 mg, once daily) from the US Food and Drug Administration (FDA) for the treatment of adults having active non-radiographic axial spondyloarthritis (nr-axSpA). The approval from the FDA is for nr-axSpA in people with objective signs of inflammation […]